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Abstract 12 
Dementia is fast becoming a global concern due to a demographic shift towards an older 13 
population. Many studies have shown that caring for a family member or friend has a 14 
profound and negative impact on the physical, emotional and psychosocial aspects of the 15 
caregivers’ life. One significant activity that a family caregiver undertakes is assistance with 16 
the management of medicines. This review was undertaken to ascertain what the issues are 17 
that affect optimal medicines use from the perspectives of people living with dementia and 18 
their caregivers, both in the community and care home settings. A literature search was 19 
conducted using electronic databases, employing a combination of search terms. A total of 16 20 
studies met the inclusion criteria. Six broad themes were identified, together with some 21 
recommendations to improve medicines use in people with dementia. Challenges to 22 
medicines use centred on medicines management and administration, the impact on the 23 
caregiver and care recipient, their partnership and interface with formal care. Future research 24 
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should focus on developing targeted interventions that can overcome these challenges to 25 
achieve optimal medicines use.  26 
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1. Introduction 30 
Population demographics in both developed and developing countries is shifting towards a 31 
population with a higher proportion of people aged 65 years of age and above (Stegemann et 32 
al., 2010). It is predicted that by 2050, the number of people aged 60 and over will reach 1.25 33 
billion globally (Prince et al., 2013) and in the United Kingdom (UK) 23% of the population 34 
will be 65 years of age or over by 2035 (ONS, 2012). The increase in life expectancy also 35 
means that the number of people suffering from dementia is on the rise. Alzheimer’s Disease 36 
International estimated that there are 46.8 million people living with dementia worldwide in 37 
2015, with that number set to double every 20 years to reach 131.5 million in 2050 38 
(Alzheimer’s Disease International, 2015). 39 
The increase in the likelihood of acquiring chronic diseases with age and resultant 40 
polypharmacy increases the risk of non-adherence (Murray et al., 2004), with unwanted 41 
clinical and economic consequences. It is imperative that patients adhere to their treatment 42 
regimen to achieve therapeutic goals. Adherence rates in the elderly are variable; but, as the 43 
amount of medicines taken and the complexity of the regimen increases, the adherence rate 44 
potentially decreases (Miller, 2008). Furthermore, adherence and ability to manage medicines 45 
can be compromised in people with cognitive impairment (Cooper et al., 2005; Ahn et al., 46 
2009; Allaire et al., 2009; Hayes et al., 2009). As people living with dementia (PLWD) 47 
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gradually lose their ability to manage their medicines appropriately, family members or 48 
friends step in to assist them. Family caregivers may take on a range of activities including 49 
administering medicines, managing side effects, and maintaining the medicinal supply 50 
(Francis et al., 2002; Smith et al., 2003). PLWDs’ ability to make decisions is also impaired 51 
(Hirschman et al., 2005). Consequently PLWD tend to rely heavily on their family caregivers 52 
to manage their medicines, which can sometimes create a burden and negatively impacts the 53 
caregiver’s quality of life (Francis et al., 2002; Smith et al., 2003; Slattum and Johnson, 2004; 54 
Cotrell et al., 2006; Sörensen et al., 2006; Arlt et al., 2008; Etters et al., 2008). 55 
Safe and effective medication use is a priority for all patients, especially older patients, due to 56 
their co-morbidities and diverse needs, and this includes tailoring the drug formulations and 57 
optimising their medication management (Orwig et al., 2006; Stegemann et al., 2010). This is 58 
even more vital in PLWD due to their decline in cognitive abilities. The medication 59 
management role of family caregivers of older people and people with cognitive impairment, 60 
the tasks they take on and the factors impacting them has been explored in a recent review 61 
(Gillespie et al., 2013), but the problems and issues with medication use faced by PLWD and 62 
their caregivers were not the main focus of the paper. Optimising medication use requires a 63 
comprehensive understanding of the issues affecting medicines management and 64 
administration in practice, both in the community and care home settings.  65 
The research question for this review was ‘What are the challenges to medicines use faced by 66 
people living with dementia and their caregivers?’. Medicines use refers to the management 67 
and administration of medicines. The term ‘caregiver’ encompasses both family caregivers 68 
and carers or nurses in care homes so that we are better able to understand the scope of issues 69 
across different care settings and level of training and in relation to people with a range of 70 
dementia severity. The review highlights the scope and range of problems experienced by 71 
PLWD and their caregivers. It focuses on problems that relate directly to medicines 72 
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management and administration, which in turn can help inform future recommendations, as 73 
well as aid in the development of targeted interventions.  74 
2. Method 75 
2.1. Search strategy  76 
A literature search was conducted to identify studies relevant to the research question using 77 
bibliographic databases such as PubMed, EMBASE, International Pharmaceutical Abstracts, 78 
Scopus, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), 79 
MEDLINE and Science Direct. Additional searches were made using the International 80 
Journal of Pharmacy Practice (IJPP) abstracts and Google (Google was used as an additional 81 
tool to identify any studies that may have been missed in the database search). No time limit 82 
restrictions were imposed when conducting the search; all databases were searched from time 83 
of inception until January 20l5. In addition, the references from the retrieved studies were 84 
manually searched for any other relevant studies. The following search terms were used: 85 
‘Dementia’ OR ‘Alzheimer’s’ OR ‘Mild cognitive impairment’ AND ‘Caregiver*’ OR 86 
‘Carer*’ OR ‘Care home*’ OR ‘Carer centre*’ AND ‘Medication*’ OR ‘Prescription*’ OR 87 
‘Pharmaceutical*’ OR ‘Drug*’ OR ‘Formulation*’ OR ‘Dosage form*’ AND ‘Barrier*’ OR 88 
‘Challenge*’ AND ‘Medication administration’ OR ‘Medication management’ OR 89 
‘Medication use’. 90 
2.2. Eligibility criteria 91 
Studies that provided either the PLWD, their caregiver’s or both of their perspectives on 92 
challenges to medication use were deemed eligible. There were no restrictions on method 93 
type; studies that used qualitative, quantitative or a mix of both qualitative and quantitative 94 
methods were included. The term ‘caregiver’ encompassed both family caregivers and carers 95 
or nurses in care homes (nursing or residential). Family caregivers were defined as family 96 
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members or friends who provided unpaid medication assistance to PLWD. Abstracts of 97 
posters were also included as they provide information on ongoing-work that is being 98 
conducted in this area, as there is limited published data available. Studies were excluded if 99 
they did not mention whether people had a form of cognitive impairment, or if they were not 100 
written in the English language. Table 1 shows the eligibility criteria used. 101 
2.3.Data extraction and analysis 102 
Information relating to problems encountered with medication management and 103 
administration to PLWD, as well as recommendations and suggestions to improve medication 104 
use were extracted from the articles. Information regarding the study design and setting, type 105 
and number of participants, sampling and recruitment, and methodology was also recorded on 106 
a data extraction sheet, which was developed by and reviewed within the research team. 107 
Regular meetings of the research team were held to discuss findings and a team approach was 108 
undertaken to the reviewing of papers. The Consolidated Criteria for Reporting Qualitative 109 
Research (COREQ) was used to appraise the qualitative studies (Tong et al., 2007). Appraisal 110 
of qualitative and quantitative studies involved an assessment of the research methods, study 111 
design and sampling. The first author (DA) conducted initial thematic analysis using an 112 
inductive approach when reading the articles to generate themes; challenges and factors 113 
impacting medicines use were extracted and recoded into themes. All authors met regularly to 114 
discuss and review emerging themes and to reach consensus on the final analysis findings. 115 
 116 
 117 
 118 
 119 
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3. Results 120 
3.1.Search results 121 
The total of 2657 citations were retrieved from searching the databases. A search using 122 
Google UK and Google Australia yielded 4 further studies that also met the inclusion criteria, 123 
bringing the total number to 2661. The titles of all citations were reviewed and 2378 studies 124 
were excluded. The abstracts and full text of the remaining 283 citations were then reviewed 125 
according to the inclusion criteria, and 270 were excluded for the following reasons: 126 
duplicates (n=64), irrelevant (n=206). An examination of the full text of the remaining 13 127 
papers confirmed that they fulfilled the eligibility criteria. After a manual search of the 128 
reference lists and citations of the retrieved articles, 3 further studies were deemed relevant. 129 
Figure 1 represents a flowchart of the literature review process.  130 
The literature review yielded 16 studies that reported issues with medicines use by PLWD 131 
and caregivers. The participants in twelve of the studies were either PLWD, their caregivers 132 
or both (Hutchings et al., 2010; Taylor and Weiss, 2010; Kaasalainen et al., 2011; Carder, 133 
2012; Jansen et al., 2012; While et al., 2012; De Witt Jansen et al., 2013; Erlen et al., 2013; 134 
Maidment et al., 2013; Poland et al., 2014; Gillespie et al., 2015; Smith et al., 2015). 135 
Participants in the other four studies were older people in general, some of whom had 136 
dementia or who were caregivers of PLWD (Travis et al., 2000; Lau et al., 2009; Reinhard et 137 
al., 2012; Mirk et al., 2013). Six of the studies were conducted in the United States of 138 
America (USA), seven in the UK, one in Canada, and two in Australia. All of the studies 139 
were conducted fairly recently, with the earliest published in 2000 and the latest published 140 
early in 2015. Thirteen studies used qualitative methods, two adopted a mixed methods 141 
approach, and one used quantitative methods. Tables 2 and 3 provide the characteristics of 142 
the retrieved studies.   143 
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Six major themes were generated from the 16 relevant studies; organisation and scheduling 144 
logistics, administration procedures and health literacy, impact on caregiver, impact on 145 
PLWD, partnership between caregiver and PLWD, and how this partnership interfaces with 146 
formal care. Each theme had sub-themes that clarified how each one affects medicines use in 147 
PLWD and their caregivers; these are shown in table 4.  148 
3.2.Quality of studies  149 
The quality of reporting varied in the qualitative studies; some criteria were not reported at 150 
all, such as the presence of nonparticipants in interviews/focus groups, while others were 151 
consistently reported such as methodology, sampling and reporting of findings. Some of the 152 
studies utilised more than one method of data collection, which strengthened the study 153 
findings and provided a more flexible method to accommodate participants (Travis et al., 154 
2000; Hutchings et al., 2010; Carder, 2012; Maidment et al., 2013; Gillespie et al., 2015). 155 
Some of the studies included were conference abstracts and therefore limited information was 156 
available in regard to methodology and sampling (Taylor and Weiss, 2010; Jansen et al., 157 
2012; De Witt Jansen et al., 2013; Maidment et al., 2013; Mirk et al., 2013).  158 
3.3.Theme 1: organisation and scheduling logistics  159 
This theme describes the issues encountered by caregivers with their medication management 160 
tasks and the skills required by them to effectively and safely manage medicines for the 161 
PLWD. One of the major barriers faced by caregivers and patients, as highlighted in most 162 
studies, was difficulties in obtaining medicines, such as filling prescriptions, and maintaining 163 
regular supplies of medicines at home (Travis et al., 2000; Lau et al., 2009; Mirk et al., 2013; 164 
Taylor and Weiss, 2010; Gillespie et al., 2015; Smith et al., 2015). Managing medications 165 
was a challenging task and necessitated various activities such as ordering and collecting 166 
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prescriptions and/or supplies from various sources, sometimes using different procedures, 167 
which complicated the task further (Smith et al., 2015). 168 
Caregivers also felt that Scheduling logistics was a daily stress, with the most common 169 
challenge being the ability to arrange their own medication schedule to correspond with that 170 
of the patient’s (Travis et al., 2000; While et al., 2012). There is also the added challenge of 171 
fitting both medication schedules alongside the caregiver’s routine. Polypharmacy and 172 
complex medication regimens can complicate this task further as caregivers stated they faced 173 
difficulties in monitoring when prescriptions needed to be filled, and in maintaining sufficient 174 
amounts of medications at home.  175 
Managing multiple medications and the procurement and maintenance of medicine stock at 176 
home were all highlighted by caregivers as a barrier to the medicines use process. Caregivers 177 
developed strategies, such as keeping a diary to aid medicines management (Smith et al., 178 
2015) or putting stickers on prescriptions to remind them to renew them (While et al., 2012), 179 
to overcome these challenges and to ensure that medicines were available for the PLWD and 180 
were given in a timely manner.  181 
3.4.Theme 2: administration procedures and health literacy 182 
This theme encompasses a variety of concerns in regards to information relating to the 183 
medicines and their administration from the perspectives of both the caregiver and the 184 
PLWD. All of the studies included in the literature review discussed issues relating to this 185 
theme.  186 
Poland et al. (2014) obtained the views of both caregivers of PLWD and HCPs on medication 187 
management and the challenges encountered. They found that simple tasks, such as preparing 188 
Fybogel™ laxative by suspending granules in water for oral administration, can become 189 
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complicated and cause distress to the caregiver and delay medicine administration; one 190 
caregiver stated that the formulation sets too quickly to be swallowed by the patient. This 191 
highlighted the impracticality of some medicines. Difficulties in administration of medicines 192 
can cause caregivers to modify formulations without consulting HCPs thus  risking the safety 193 
and efficacy of  medicines (Erlen et al., 2013; Mirk et al., 2013; Gillespie et al., 2015). 194 
Tailored formulations need to be prescribed to PLWD to aid the administration process, such 195 
as prescribing liquids to patients with swallowing difficulties (Kaasalainen et al., 2011). In 196 
the study by Travis et al. (2000), 32% of caregivers’ accounts related to difficulties in 197 
administration of medicines; caregivers of PLWD experienced more stress than those of other 198 
caregivers. This was due to this patient groups` cognitive decline and behavioural problems 199 
which can potentially make medicine administration a challenging task (Travis et al., 2000; 200 
Kaasalainen et al., 2011; De Witt Jansen et al., 2013). Other more general issues identified 201 
were complicated instructions, such as how to give medicines, and making decisions on when 202 
to withhold or give medicines, especially those which are Pro Re Nata (PRN). 203 
Knowledge concerning medicines was also an important issue that affected caregivers’ 204 
decisions regarding administration (Lau et al., 2009; While et al., 2012; Maidment et al., 205 
2013; Poland et al., 2014; Gillespie et al., 2015; Smith et al., 2015). Caregivers of PLWD 206 
highlighted the importance of patient information leaflets, but still faced difficulties in 207 
making judgements regarding medicines use (Smith et al., 2015). One study demonstrated the 208 
importance of caregivers being aware of dosages in case of labelling errors, (Taylor and 209 
Weiss, 2010). Poor vision and manual dexterity were other barriers to medicines use (While 210 
et al., 2012; Mirk et al., 2013; Gillespie et al., 2015). A complex medicine regimen with four 211 
or more medicines, doses that required adjustment by the caregiver and a variety of dosage 212 
forms to be administered can also be a barrier to optimum medicines use, increasing 213 
caregiver stress (Kaasalainen et al., 2011; Reinhard et al., 2012; Maidment et al., 2013; Mirk 214 
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et al., 2013; Gillespie et al., 2015). Some caregivers stated that they had to develop strategies 215 
to overcome some of these challenges, such as the use of multi compartment compliance aids, 216 
reminders, or placing medicines near their bed (Hutchings et al., 2010; Kaasalainen et al., 217 
2011; While et al., 2012; Gillespie et al., 2015; Smith et al., 2015). Some of the strategies 218 
adopted by caregivers were not always safe and effective, as found by Gillespie et al., (2015) 219 
where caregivers placed medications for the PLWD in unlabelled easy-to-open containers to 220 
assist the PLWD in overcoming their dexterity problems and to maintain their independence.   221 
One study focused on the factors affecting the decision to administer PRN medicines to 222 
residents with dementia by paid carers in care homes (Carder, 2012) and found that the 223 
decision process can be a complicated one, influenced by various issues. PLWD were not 224 
always able to verbalise their need for a certain medication, such as for pain relief. The med 225 
aide would have to know the patient very well to be able to successfully interpret their 226 
request by studying their behaviour and nonverbal cues. De Witt Jansen et al., (2013) 227 
conducted their study at nursing homes to explore the experiences of staff in administering 228 
medicines to dementia patients. The authors found several barriers to the medication 229 
management and administration procedures that could either be attributed to factors relating 230 
to the PLWD or factors relating to the work environment. Disease severity, cognitive 231 
capacity, physical disability and difficult behaviours were all barriers. Environment-related 232 
factors included interruptions by colleagues or the PLWD’s family members, distractions and 233 
the ratio of staff to residents. Staff members all agreed that the solution to overcoming 234 
barriers to medicine administration at nursing homes was effective communication with 235 
everyone involved; the residents, their relatives and the HCPs. This was also found in 236 
Carder’s (2012) study.  237 
 238 
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3.5.Theme 3: impact on caregiver 239 
Caregivers can sometimes feel ill-prepared for the role they have taken on (Maidment et al., 240 
2013; Poland et al., 2014). Taking on this role and managing medicines can disturb their daily 241 
routine and affect what activities they can take part in, especially if they do not live with the 242 
PLWD (Hutchings et al., 2010; Reinhard et al., 2012; Smith et al., 2015). Furthermore, it can 243 
cause them anxiety when they cannot cope with the pressures involved in this role; this may 244 
make them feel that they are inadequately supporting the care recipient (Poland et al., 2014). 245 
Caregivers’ concerns regarding the PLWD changed along the progression of dementia. At the 246 
mild stage caregivers focused on starting anti-dementia medications and acquiring 247 
information regarding the condition (Jansen et al., 2012). As the condition progressed to the 248 
moderate-severe stage, caregivers were more anxious about the issues they faced with the 249 
administration of medicines and how to make adherence easier. At this stage, the burden of 250 
caregiving was more evident. The role they adopted with medication assistance also changed 251 
as the PLWD’s cognitive abilities deteriorated. At the early stages of the condition, they may 252 
take on a minor role with managing medications such as requesting blister packs to be made 253 
by the pharmacist (Gillespie et al., 2015). At the moderate to severe stages, the caregiver 254 
takes on a much greater role and develops strategies for safe and effective medication use.   255 
Staff administering medications to PLWD at care homes stated that the skills required to care 256 
for people with dementia differed from other residents; for example, there was a need to be 257 
more patient and empathetic (De Witt Jansen et al., 2013). When PLWD start refusing 258 
medications, staff members had to make ethical judgments on administration of medicines, 259 
and felt that the pharmacist was the best source of assistance in this case. Caregiving staff at 260 
care homes identified the need for more efficient training concerning medication 261 
administration to dementia patients, such as the appropriateness and acceptability of available 262 
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formulations for PLWD and effective pain management. They also expressed a need to rely 263 
on their skills in understanding each individual resident to better care for them (Carder, 2012; 264 
De Witt Jansen et al., 2013). 265 
Managing and administering medicines has a direct impact on the caregiver. The 266 
responsibility involved in managing medicines  negatively affects the caregivers’ quality of 267 
life, restricting their time and activities elsewhere, thus causing carer burden (Jansen et al., 268 
2012; While et al., 2012; Gillespie et al., 2015; Smith et al., 2015). This role has been taken 269 
on by friends or family members; it was deemed a personal responsibility by themselves, by 270 
PLWD, or by society (Reinhard et al., 2012). Family carers may take on this role without any 271 
form of support and without prior knowledge of what the role involves (Reinhard et al., 2012; 272 
While et al., 2012). Some caregivers stated that they were not provided with any information 273 
about the prescribed medicines. Furthermore, no support or information regarding medicines 274 
use, such as medication use reviews, was offered to them by their pharmacist (Taylor and 275 
Weiss, 2010). Carers feel that they can only depend on themselves and any past experiences 276 
that may assist them; in fact, caregivers become so engrossed in the role that they are 277 
reluctant to have someone else take on the responsibility of the PLWD’s medicines (While et 278 
al., 2012; Smith et al., 2015). However, this was not always the case, as some caregivers were 279 
relieved when other family members assisted in managing medications or finding information 280 
on medicines (Gillespie et al., 2015). 281 
3.6.Theme 4: impact on PLWD 282 
The PLWD is central to any discussion on challenges to medicines management; the 283 
caregiver may be responsible for managing the medicines but the PLWD is profoundly 284 
affected by the process. PLWD and their caregivers all stress the importance of the PLWD 285 
retaining their independence and autonomy (Kaasalainen et al., 2011; Poland et al., 2014; 286 
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Gillespie et al., 2015; Smith et al., 2015). This can have a positive effect on PWLD taking 287 
their medicines as they still feel in control of at least one aspect of their lives.  288 
The PLWD’s cognitive abilities and severity of dementia have a strong influence on how they 289 
take their medications. One study illustrated how PLWD dealt with medicine management as 290 
their disease progressed (Kaasalainen et al., 2011). PLWD can sometimes refuse to take 291 
medicines when they are distressed or confused due to their disease. At the early stages, they 292 
may refuse because they do not want to relinquish control over their lives (While et al., 293 
2012), or because they believe that what they are experiencing is a normal part of the aging 294 
process (Gillespie et al., 2015). This can lead to anxiety over their loss of independence. As 295 
the dementia progresses, their reasons for refusing to take medications change to delusional 296 
beliefs and paranoia of being poisoned, challenging behaviours or believing that they do not 297 
require these medicines (While et al., 2012; Gillespie et al., 2015). People at the severe and 298 
end stages of the condition were found to be mostly compliant, but their challenges to 299 
medicine taking were now due to difficulties remembering how to take medicines or 300 
swallowing them (De Witt Jansen et al., 2013). In addition, any changes to their environment 301 
or transition in their care may have a drastic effect on their abilities to manage and take their 302 
medicines (While et al., 2012).  303 
3.7.Theme 5: partnership between caregiver and PLWD 304 
The partnership between the caregiver and the PLWD is crucial to medicines use. Some 305 
caregivers feel they need to empower the PLWD by allowing them to feel more in control of 306 
their medicines, and this strengthens the relationship between the two parties (Poland et al., 307 
2014). Caregivers need to be vigilant to discern when PLWD need help, as their transition 308 
from self-management to caregiver-led management is often variable and difficult to predict 309 
(While et al., 2012). This constant task of assessing the PLWD’s capabilities to manage and 310 
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take their own medicines has been described as very taxing by some caregivers (Gillespie et 311 
al., 2015). Some of the signs that might indicate that the caregiver needs to provide assistance 312 
with medicines includes the PLWD forgetting to refill prescriptions, forgetting when and how 313 
to take the medications and forgetting the information given to them by their GP or 314 
pharmacist (Gillespie et al., 2015). Administration of some medicines can also pose some 315 
problems; some dosage forms can cause discomfort when being administered, such as 316 
suppositories, inflicting stress on the caregiver and affecting their relationship with the care 317 
recipient.  318 
The transition process impacts both the PLWD and their caregiver; the PLWD is either 319 
reluctant to release their autonomy or welcomes the assistance, and the caregiver needs to 320 
make the transition as easy and smooth as possible (While et al., 2012). Caregivers have to 321 
balance their efforts at allowing the PLWD to retain their autonomy, such as involving the 322 
PLWD in information and decisions about their medicines, with their feelings of anxiety at 323 
doing so (Smith et al., 2015). 324 
Gillespie et al., (2015) found that some caregivers did not trust the PLWD to manage and 325 
take their medications as instructed and always had to be vigilant. Trust is required between 326 
both, especially when the PLWD is transitioning from self-management to caregiver-led 327 
management. The relationship needs to be transparent, with both parties working together to 328 
ensure that medicines are being taken in a safe and effective way.   329 
3.8.Theme 6: interface with formal care 330 
This theme describes the relationship between HCPs, such as GPs, pharmacists and staff at 331 
care homes, and the caregiver-PLWD dyad. Some caregivers felt that HCPs do not fully 332 
comprehend the role that caregivers have taken on and the burden and stress involved with it 333 
(Poland et al., 2014). This can lead to caregivers not sharing their medication-related 334 
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concerns, thereby increasing their burden (Lau et al., 2009). Furthermore, caregivers felt they 335 
were not being involved by the GP in discussions and decisions about the PLWD’s 336 
medication, such as when medications were changed or new ones prescribed (Jansen et al., 337 
2012; Gillespie et al., 2015; Smith et al., 2015). The opposite also occurs, where the GP 338 
completely disregards the care-recipient in the consultation and talks directly to the caregiver, 339 
causing distress to the PLWD (Smith et al., 2015). There is also the issue of the limited 340 
consultation time, causing some caregivers not to voice their concerns or ask for more 341 
information, as well as the inaccessibility of some HCPs (Smith et al., 2015). 342 
Gillespie et al., (2015) explored caregivers’ views from ethnic minority groups in Australia 343 
regarding support from HCPs. Some caregivers voiced their contentment with their 344 
relationship with their HCPs, sometimes relying on them to advise and mediate, as the PLWD 345 
respects them and would comply with their instructions. Not all caregivers had access to a 346 
pharmacist who provided assistance, even when the pharmacist was aware that a person had 347 
dementia.    348 
A strong relationship between the caregiver-PLWD dyad and HCPs where communication is 349 
invited is necessary to facilitate medicines management (Kaasalainen et al., 2011). Caregiver 350 
and patient support, such as education, should also be provided, to ease the hassles involved 351 
with the management of medicines and ensure both the caregiver and PLWD are confident in 352 
their roles (Kaasalainen et al., 2011). Both PLWD and their caregivers value their 353 
relationship with their HCPs and its continuity; they need to trust the HCPs to be able to 354 
depend on them (While et al., 2012).  355 
3.9. Recommendations to improve medicines use in PLWD 356 
The studies all provided recommendations for improvements from the participants, the 357 
authors or both. Most studies emphasised the importance of promoting communication 358 
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between the PLWD and their caregiver, between them and HCPs, and between HCPs 359 
themselves (Lau et al., 2009; Kaasalainen et al., 2011; Jansen et al., 2012; Reinhard et al., 360 
2012; While et al., 2012; De Witt Jansen et al., 2013; Poland et al., 2014; Gillespie et al., 361 
2015; Smith et al., 2015). Better communication can assist in building trust and shed light on 362 
the problems experienced to allow them to be addressed appropriately. In addition, involving 363 
both the caregiver and the PLWD in decisions was also seen as a way to overcome barriers 364 
and encourage them to voice their concerns so that HCPs are made aware of any medication 365 
hassles experienced. Furthermore, HCPs need to be more accessible to caregivers and the 366 
PLWD. Communication problems and inaccessibility of HCPs have been cited elsewhere as 367 
problems faced by PLWD/older people and their caregivers (Bruce et al., 2002; Francis et al., 368 
2006; Prorok et al., 2013). 369 
The provision of clear information regarding medicines is vital (Travis et al., 2000; 370 
Hutchings et al., 2010; Kaasalainen et al., 2011; Reinhard et al., 2012; While et al., 2012; 371 
Erlen et al., 2013; Gillespie et al., 2015; Smith et al., 2015). This can be given to caregivers 372 
and PLWD orally or written during consultations, by the pharmacist when dispensing the 373 
medicines and through education. Information should be specific to each person and should 374 
include what the medicines are, what they do, the dose to be given, the best ways to 375 
administer the medicine, side effects that may be experienced and if any changes have been  376 
made to the medicine.  377 
Another recommendation was to deliver tailored support and training and better services that 378 
meet the needs of caregivers and PLWD (Lau et al., 2009; Hutchings et al., 2010; Taylor and 379 
Weiss, 2010; Kaasalainen et al., 2011; Carder, 2012; Reinhard et al., 2012; While et al., 380 
2012; De Witt Jansen et al., 2013; Erlen et al., 2013; Mirk et al., 2013; Poland et al., 2014; 381 
Gillespie et al., 2015). Training and support should focus on improving medication 382 
management and administration skills, especially regarding PLWD refusal to take the 383 
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medicine, the modification of medicines to improve patient acceptability and dosage 384 
adjustment. Support and services should be well publicised for them to be utilised by PLWD 385 
and their caregivers. Training should be tailored to each stage of dementia, and repeated from 386 
time to time so that information and skills are retained. Furthermore, training on the best 387 
ways of administering medicines and the different dosage forms available should also be 388 
given to care home staff to optimise the acceptability for the PLWD.  389 
Medication reviews by pharmacists were welcomed by caregivers and PLWD as a way to 390 
receive tailored advice and information, as well as a means to relay any medication-related 391 
hassles they may be experiencing. Pharmacist-led medication reviews have been shown to 392 
improve adherence and medicine knowledge in older people (Holland et al., 2008). Strategies 393 
employed by caregivers and PLWD to ease medication management include the use of 394 
reminders and a variety of compliance aids, such as dosette boxes. These should be assessed 395 
by the HCP to ensure the caregiver and/or care recipient are able to use them and find them 396 
helpful. It was also suggested that doctors should re-evaluate prescriptions to assess the need 397 
for medicines, simplify regimens and improve dosage forms, such as switching a patient from 398 
a solid to liquid formulation when swallowing difficulties were present.    399 
4. Discussion  400 
This review has shown that some data is available on the challenges in regard to medication 401 
management and administration in older people. However, not all studies were exclusive to a 402 
dementia population; some included a wider sample of older people, some of whom had 403 
dementia; others were caregivers of people living with dementia. Medicines use in this 404 
population may provide added difficulties for caregivers as a result of issues relating to 405 
cognitive impairment (Poland et al., 2014). There is a distinction between the care provided 406 
in the two types of care homes; this may have an implication on the findings because of the 407 
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level of training of staff members. Although six different themes and recommendations for 408 
improvement were found, there is some overlap.  409 
Administering medicines was shown to be a huge component of being a caregiver of PLWD 410 
and had many difficulties associated with it (Travis et al., 2000; Reinhard et al., 2012). It is 411 
further complicated by polypharmacy, a variety of dosage forms and difficulty to interpret 412 
instructions (Maidment et al., 2013), all affecting optimal medicines use. Travis et al., (2000) 413 
demonstrated that whilst all caregivers faced difficulties when administering and managing 414 
medicines, those caring for cognitively impaired individuals experienced more difficulties. 415 
This can be attributed to the patient refusing to take medicines, causing the caregiver to get 416 
frustrated (Reinhard et al., 2012; Gillespie et al., 2015). Barriers to medicines management 417 
and administration for caregivers of PLWD were not limited to dementia-specific medicines, 418 
but to all medicines and dosage forms being administered (Poland et al., 2014). Something as 419 
simple as applying eye drops can turn into a lengthy process. Even making a decision about 420 
whether the person requires pain relief can pose difficulties as it is sometimes challenging for 421 
the PLWD to express their pain. The administration of medicines can also be hindered by the 422 
PLWD developing difficulties swallowing or forgetting how to take medicines (Smith et al., 423 
2015; Gillespie et al., 2015).  424 
In care homes, better communication with the healthcare team, the PLWD and their family 425 
were expressed to be essential to the administration of medicines. Furthermore, staff 426 
administering medicines in care homes had to possess certain skills to be able to understand 427 
each PLWD individually to make the process of medicine administration safe and effective 428 
(Carder, 2012; De Witt Jansen et al., 2013).   429 
The degree of cognitive impairment is a major issue and affects various activities, including 430 
medicines administration and negotiating the transition from self to caregiver-led 431 
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management. While two studies attributed barriers to medicines management to dementia 432 
severity (Kaasalainen et al., 2011; Jansen et al., 2012), another study associated problems 433 
with medicines management and administration with regimen complexity rather than 434 
dementia severity (Erlen et al., 2013).  435 
The partnership between the PLWD and their caregiver was a critical component of the 436 
medicines use process; it was seen as a continuous struggle due to issues such as the PLWD 437 
refusing to take medicines and their need to retain their independence (While et al., 2012). 438 
The transition to caregiver-led management may not go smoothly as the PLWD can resent the 439 
help offered. Also, caregivers cannot always discern at what stage the PLWD can no longer 440 
manage their medicines safely and effectively (Poland et al., 2014; Gillespie et al., 2015).  441 
Caregivers often lacked the knowledge required to make certain decisions (While et al., 442 
2012). The care-giving role they take on often entails making complex judgements regarding 443 
medicines use for the PLWD, adding more to their stress (Maidment et al., 2013).  444 
Study findings also illustrated how caregivers lacked medication-related support (Travis et 445 
al., 2000; Taylor and Weiss, 2010; Poland et al., 2014; Gillespie et al., 2015; Smith et al., 446 
2015). Family caregivers sometimes modify medicines, such as crushing tablets, or conceal 447 
them in food to ease medicine administration to those who have difficulties swallowing or 448 
refuse to take medicines. They may not realise that this can affect the therapeutic outcome, 449 
leading to lack of quality, safety and efficacy of the medicine (Gillespie et al., 2015). 450 
General support and services aimed at PLWD and their caregivers have been highlighted as 451 
requiring improvement (National Audit Office, 2007). There is a need for improved systems 452 
regarding the provision of medicines-related information, such as the importance of the 453 
treatment, expected side effects and administration procedure, for PLWD and their caregivers 454 
to ensure optimal medicines use and adherence (While et al., 2012).  455 
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Findings emphasise the importance of maintaining a good relationship between the 456 
caregiver-PLWD dyad and HCP; effective communication and trust can assist the caregiver 457 
in coping with the pressures, thereby allowing the PLWD to be cared for at home for a longer 458 
time (While et al., 2012; Poland et al., 2014).    459 
The literature also highlights the role that HCPs could play in overcoming some of the issues 460 
through better communication, inclusion of both PLWD and their caregivers in discussions 461 
and decisions, and provision of detailed and individualised medication information. The role 462 
of the pharmacist was stressed as being integral to this. Pharmacists are an accessible and 463 
approachable source of information and support in the community. Pharmacists can also have 464 
a major role in care homes by supplying advice to nurses and carers on medication 465 
administration and dosage forms, as well as reviewing medicines. Older people have been 466 
shown to benefit from pharmacist-led interventions (Ryan et al., 2014). There is a need for 467 
consistency in the advice and reviews administered to PLWD and their caregivers to ensure 468 
there is no confusion 469 
Interventions to improve medicines use in PLWD have not been widely documented and 470 
have either focused on other diseases, such as diabetes, or on adherence (Ryan et al., 2014). 471 
A recent systematic review found 75 studies of interventions to improve medicines use (Ryan 472 
et al., 2014). Some studies employed one intervention, such as simplifying the medication 473 
regimen, while others offered a mixed approach, such as different forms of education. 474 
Although single interventions have been shown to improve medicine knowledge and use, the 475 
use of multiple interventions provides a broader scope. Very few interventions concentrated 476 
on skills and communication; both have been emphasised as pivotal to overcoming barriers to 477 
medicines use in the current review.  478 
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A systematic review of interventions to improve adherence in people with cognitive 479 
impairment included only 3 studies (Campbell et al., 2012). The interventions ranged from 480 
reminders and compliance aid medication boxes at the care recipients’ home, a 481 
telephone/televideo medication reminder, and refill reminder postcards and medication 482 
schedules. Findings did not show significant benefits, but a recurring message was the 483 
importance of continuous interaction and communication with PLWD.  484 
Awareness needs to be raised regarding the common practice of modifying the original form 485 
of the medicine; caregivers should be provided with information and support to choose safe 486 
and effective alternative strategies when administering medicines. Medicine-focused training, 487 
such as the use of alternative dosage forms, was suggested as a solution to overcome barriers 488 
to the administration of medicines to residents with dementia (De Witt Jansen et al., 2013).   489 
5. Implications for research  490 
This review has shed light on some gaps in knowledge, which includes how PLWD and their 491 
caregivers cope with deteriorating cognitive impairment and other physical difficulties that 492 
arise due to the progression of dementia that might affect how medicines are used. 493 
Contradictory findings require further research to confirm whether the degree of cognitive 494 
impairment or regimen complexity act as a barrier to medicines use. 495 
Future studies should also examine the implications of choice of different routes of 496 
administration and dosage forms and should endeavour to include the views of both PLWD 497 
and their caregivers. Recommendations can then be given to achieve patient-centric care 498 
regarding effective medicines use for PLWD. Healthcare professionals also need to 499 
understand the importance of asking about how medicines are being taken or given to ensure 500 
they are being adhered to and administered safely and effectively, leading to acceptability 501 
both for PLWD and their caregiver. There is also a need for better education and support 502 
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provision, and future research should focus on interventions with a wider scope that do not 503 
focus on adherence but on the medication use process to improve medicines use for this 504 
population. In order for interventions to be successful, the needs of PLWD and their 505 
caregivers need to be taken into account when developing them (Brodaty and Donkin, 2009).   506 
6. Limitations 507 
This review does not include many studies, but this may be attributed to the specificity of the 508 
research question. Furthermore, this highlights that this topic may not be well-researched. 509 
Some of the findings included were from conference abstracts; although the findings may not 510 
always be as comprehensively peer-reviewed as journal articles, they widen the scope of the 511 
issues. Many of the studies had small sample sizes; this can be due to the qualitative methods 512 
used and the difficulty in recruiting PLWD and their caregivers (Hutchings et al., 2010; 513 
Goodman et al., 2011).  514 
7. Conclusion 515 
Dementia is a debilitating syndrome that affects both the patient and their caregiver, and the 516 
number of people suffering from it will steadily increase as the population is ageing. 517 
Although much work has been done to raise awareness of dementia, the focus has been on its 518 
diagnosis and management. Medication use may be a minor aspect of the disease but, if 519 
overlooked, can negatively affect management of the condition. The challenges associated 520 
with medicines use in PLWD should be addressed and should include the perspectives of all 521 
those involved: the PLWD, their family caregiver and their HCP. Studying challenges to 522 
medicines use along the progression of dementia can assist in developing targeted 523 
interventions to improve medicines management for this patient population.  524 
 525 
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Table 1: Eligibility criteria for included studies  
Eligibility criteria 
Qualitative, quantitative, or mixed-methods 
Perspective of PLWD, caregiver, or both 
Caregivers included family caregivers and 
carers or nurses from care homes 
States that patients have form of dementia 
In the English language 
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Table 2: Characteristics of qualitative studies  
Author Country Type (number) 
of participants 
Method of data 
collection 
Methodology Aim of the study 
Travis et al. 
(2000) 
 
USA Family 
caregivers (23)   
Interviews Content analysis To identify medication administration hassles from the 
perspectives of family caregivers of older patients 
Lau et al. 
(2009) 
USA Hospice 
providers (22), 
family caregivers 
(23)  
Interviews Content analysis, 
thematic coding 
To identify family caregiver medication management skills for 
home hospice patients 
Hutchings 
et al. (2010) 
UK Family 
caregivers (11), 
PLWD (12) 
Interviews, 
focus groups 
Thematic analysis To learn PLWD and caregivers’ experiences of using 
cholinesterase inhibitors  
Taylor and 
Weiss 
(2010) 
UK 7 case groups; 
each group 
consisting of the 
PLWD, their 
main caregiver 
and the PLWD’s 
prescriber 
Interviews Interpretative 
phenomenological 
analysis 
To explore the views on dementia medicines from PLWD in the 
early stage of the condition, their main caregiver and their 
prescriber over time. 
Kaasalainen 
et al. (2011) 
Canada HCPs (26), 
family caregivers 
(20), PLWD (11) 
Interviews Grounded theory To explore medication management experiences from the 
perspectives of PLWD in the community, their informal 
caregivers, and HCPs who are involved in their care 
Carder 
(2012) 
 
 
 
 
USA Paid carers at 
care homes (16) 
Interviews, 
observation 
Grounded theory To explore care home staff members’ decision-making process 
to administer PRN medications to residents with dementia  
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Author Country Type (number) 
of participants 
Method of data 
collection 
Methodology Aim of the study 
Jansen et al. 
(2012) 
UK Bereaved 
caregivers (6), 
HCPs (6) 
Interviews Narrative analysis To explore caregivers’ and HCPs’ experiences regarding 
decisions about medication options for PLWD at end-of-life care 
 
While et al. 
(2012) 
Australia Family 
caregivers (9), 
PLWD (8) 
Interviews Grounded theory To explore the medication management experiences of PLWD in 
the community and their informal caregivers and comparing 
their perspectives with those of people without dementia 
De Witt 
Jansen et al. 
(2013) 
UK Nurse home 
managers (3), 
nursing staff (8) 
Interviews Thematic analysis To explore nursing home managers’ and staff members’ 
experiences of administering medicines to residents with 
dementia  
Mirk et al. 
(2013) 
USA Family 
caregivers (19), 
elderly people 
(27) 
Medication 
management 
visit 
Not reported To employ the IMPROVE model to determine problems 
encountered by elderly patients and their informal caregivers 
with medication management  
Poland et 
al. (2014) 
UK Family 
caregivers (9) 
Focus group Thematic and 
narrative analysis 
 
To gain caregivers perspectives on medication issues and how 
they are dealt with 
Smith et al. 
(2015) 
UK Family 
caregivers (14), 
PLWD (5) 
Interviews Thematic analysis 
 
To identify the types of medicines-related assistance provided by 
family caregivers of PLWD and the problems surrounding it 
Gillespie et 
al. (2015) 
Australia Family 
caregivers (29) 
Interviews, 
Focus groups 
Thematic analysis To examine the medication management experiences of ethnic 
minority family caregivers of PLWD  
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Table 3: Characteristics of studies that employed quantitative or mixed methods 
Author Country Type (number) 
of participants 
Method of data 
collection 
Methodology Aim of the study 
Reinhard et 
al. (2012) 
USA Family caregivers 
(1,677) 
Online survey NA To learn the responsibilities of family caregivers relating to 
medical tasks and the difficulties encountered  
 
 
 
Erlen et al. 
(2013) 
USA Family caregivers 
(91), PLWD (91) 
Interviews, 
questionnaires, 
telephone 
follow-up 
Not reported To examine medication management deficiencies, as well as 
medicine taking issues, encountered by PLWD and their 
caregivers in the community  
Maidment 
et al. (2013) 
UK Alzheimer’s 
Society Research 
Network 
Volunteers (20), 
family caregivers 
Focus group, 
survey 
Not reported To explore the role of informal caregivers relating to safe 
medication management and the issues involved 
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Table 4: Themes derived from the studies  
Theme Sub-themes 
Organisation and 
scheduling  
Logistics
1,2,4,8,11,15,16
 
 Scheduling multiple medications throughout the day and giving them on time 
 Acquiring, storing, and tracking medications 
 Coordinating personal medication schedules with those of the PLWD 
Administration 
procedures and health 
literacy
1-6, 8-16
 
 Giving medication to a disoriented/difficult PLWD 
 Deciding when to hold, adjust, or discontinue a medication, especially PRN medicines  
 Learning how to administer different types of dosage forms and medicines that can be invasive  or distressing  
 Having a good understanding of the medicines being given such as difference between brand and generic names 
 Employing strategies to aid medication use 
 Dealing with polypharmacy and medication complexity  (number and frequency of medications) 
 Having dexterity problems, poor vision, or swallowing difficulties  
Impact on  
caregiver
1, 3-16
 
 Managing medications and administration impacted on caregivers’ time and lives by restricting activities and causing 
burden  
 Medication management described as emotionally difficult and frightening  
 Reluctance in relying on others for support 
 Difficulties accessing support to ensure safe and effective medicines use 
 Role taken with little choice, support, skills, or medication knowledge. (feelings of personal responsibility) 
 How caregivers’ concerns and feelings regarding medicines use change as dementia progresses 
 Skills/training needed by formal caregivers when dealing with PLWD 
Impact on  
PLWD
5, 8-10, 14-16
 
 PLWD need to retain autonomy/independence  
 PLWD refusal to take medications due to denial (early stage) or delusions (severe stage) 
 PLWD affected by transition in care and change in environment 
Partnership between 
caregiver and  
PLWD
8, 5, 14-16 
 Trust needed between patient and caregiver  
 Transition from self-management to caregiver-led management 
 Inclusion of caregiver and PLWD in decision-making 
Interface with formal 
care
2, 5, 7, 8, 14-16 
 Need to communicate effectively with HCPs about medication-related issues (communication barriers and facilitators) 
 Trust and continuity between HCPs, caregivers and PLWD 
 Accessibility of HCPs 
 Inclusion of both caregiver and PLWD in discussions and decisions  
1. (Travis et al., 2000), 2. (Lau et al., 2009), 3. (Hutchings et al., 2010), 4. (Taylor and Weiss, 2010), 5. (Kaasalainen et al., 2011), 6. (Carder, 2012), 7. (Jansen et al., 2012),  
8. (While et al., 2012), 9. (Reinhard et al., 2012), 10. (De Witt Jansen et al., 2013), 11. (Mirk et al., 2013), 12. (Erlen et al., 2013), 13. (Maidment et al., 2013), 14. (Poland et al., 
2014), 15. (Gillespie et al., 2015), 16. (Smith et al., 2015)  
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